NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression (SevereBD)
Administration of Intravenous NRX100 (Ketamine) vs Placebo Infusion for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Patients With Bipolar Depression
Sponsor: NeuroRx, Inc.
A PHASE3 clinical study on Bipolar Depression and Suicidal Ideation, this trial is ongoing. The trial is conducted by NeuroRx, Inc. and has accumulated 16 data snapshots since 2019. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
16 versions recorded-
Feb 2026 — Present [monthly]
Unknown PHASE3
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Feb 2026 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Feb 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
Status: Unknown Status → Active Not Recruiting
-
Oct 2023 — Feb 2024 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
▶ Show 11 earlier versions
-
Oct 2021 — Oct 2023 [monthly]
Recruiting PHASE3
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Jan 2020 — Nov 2020 [monthly]
Recruiting PHASE3
-
Aug 2019 — Jan 2020 [monthly]
Recruiting PHASE3
Status: Active Not Recruiting → Recruiting
-
Jul 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE3
Status: Not Yet Recruiting → Active Not Recruiting
-
Jan 2019 — Jul 2019 [monthly]
Not Yet Recruiting PHASE3
-
Dec 2018 — Jan 2019 [monthly]
Not Yet Recruiting PHASE3
-
Jun 2018 — Dec 2018 [monthly]
Not Yet Recruiting PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE3
-
Feb 2018 — Apr 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- NeuroRx, Inc.
- Target Health Inc.
For direct contact, visit the study record on ClinicalTrials.gov .